Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario

Conclusion: CIMAvax-EGF, as an EGF depleting immunotherapy used as switch-maintenance was safe and effective in patients with NSCLC.PMID:37056397 | PMC:PMC10088885 | DOI:10.7150/jca.67189

Source: Cancer Control - April 14, 2023 Category: Cancer & Oncology Authors: Yoanna I Flores Vega Diana L P áramo González Sof ía C Alsina Sarmiento Luis E Alsina Tul Iris B Inguanzo Vald és Jorge Rodr íguez Machado Ángel Elejalde Larrinaga Justo E Flores Rodr íguez Janet Lamadrid Garc ía Danay Corrales Otero Ram ón Roper Source Type: research